Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFIRM: Seladelpar in Primary Biliary Cholangitis with Compensated Cirrhosis
2024-516525-31-01Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Seladelpar with Placebo (2 arms). Primary endpoint: Event-free survival (EFS). Planned start Jul 2025; status: authorised.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-516525-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516525-31-01.